INTRODUCTION
Vascular malformations are a non-tumorous subset of vascular anomalies thought to arise through developmental dysmorphogenesis. Accompanying refinements in the clinical classification of vascular malformations has been the identification of associated gene mutations (for a comprehensive review 1). Fast-flow malformations affect arteries alone, vessels of mixed arterialvenous identity (AVM) and AVMs with lymphatic and/or capillary involvement (2, 3) . These have been causally linked to autosomally dominant mutations affecting growth-regulating genes such as RASA1 and phosphatase and tensin homolog (PTEN), and specification genes such as endoglin (ENG) and ALK1 (1, 3) . Alternatively, slow-flow lesions affect capillaries, veins and lymphatics individually or in combination. Mutations in GNAQ and TIE2, the majority of which are somatically acquired, have been linked to port-wine stains (capillary malformations) and venous malformations, respectively (4, 5) . Inherited mutations in multiple genes (KRIT1, PDCD10 and malcavernin) have been implicated in the capillary anomaly cerebral cavernous malformation (1, 3) . Mutations in lymphaticspecific genes such as FOXC2, FLT4 and SOX18 have been associated with inherited forms of lymphedema (1, 6) , but an etiopathologic basis remains to be established for lymphatic * To whom correspondence should be addressed at: Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital and Medical Center, MLC 2023, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA. Tel: +1 5136363240; Fax: +1 5136367657; Email: belinda.dickie@cchmc.org malformations (LMs). The appearance of LMs in syndromic overgrowth conditions does, however, implicate growth-regulating genes (see later).
LMs are congenital lesions comprised dilated lymphatic channels or fluid-filled cysts. Lesions occur sporadically anywhere in the body though most occur in the head and neck region. They can be localized, multifocal or diffuse, extending into the chest, abdomen and limbs. They do not regress but grow proportionally with the growth of the child. Clinical descriptions reflect the nominal size of the lymphatic channels, microcystic versus macrocystic (1, 7) , or its complexity in terms of vascular involvement. For example, they can be limited to lymphatic vessels, have a venous component (veno-lymphatic malformation, VLM), or be associated with a mixed capillary-venous malformations (capillary-venous-lymphatic malformation, CVLM). Though relatively rare, LMs can be associated with significant pain and morbidity if infiltrative. Traditional treatment options are supportive and based on treating the symptoms of the patient. These include compression, sclerotherapy and debulking surgery. Chemotherapeutic treatments (sirolimus, for example) are currently being evaluated in clinical trials as a means to reduce lymphatic bulk and minimize complications such as infections, pain and fluid leakage (8) . Identifying the genetic basis of disease will expand avenues of therapeutic intervention, as will clarifying the cellular basis of LMs. Presently, the affected cell type could be lymphatic endothelium, an endothelial precursor, a vascular stromal cell or even an embryonic cell linked to the perturbation of vessel architecture and lymphatic flow (9, 10) .
Lymphatic anomalies are a feature of related overgrowth syndromes in which known gene mutations are a determining factor. This provides a clue to the molecular and cellular factors underlying the development of LMs. LMs are a common component of CLOVES (congenital lipomatous asymmetric overgrowth of the trunk with lymphatic, capillary, venous, and combined-type vascular malformations, epidermal nevi, and skeletal anomalies) (OMIM612918), Klippel-Trenaunay (KTS; OMIM149000) and Proteus (OMIM176290) syndromes, all of which have been linked to mutations affecting the receptor tyrosine kinase-PI3K-AKT growth pathway (11) (12) (13) (14) . Alternatively, lymphatic dysplasia, vessel dilation and lymphangiectasia has been associated with two other syndromes, Noonan (OMIM163950) and Parkes Weber (OMIM608355), linked to mutations in the RAS-MEK-ERK growth pathway (15, 16) .
Our objective was to explore the lymphangiogenic profile of lesion-derived lymphatic endothelial cells (LM-LECs) as a basis of disease. Loosely overlapping LECs line the fenestrated capillaries of the distal lymphatic system. These take up interstitial fluid and immune cells which are propelled through muscularized collecting lymphatic tubules. Unidirectional flow is maintained by the existence of valves in the collecting vessels as fluid is moved through draining lymph nodes and returned to the central circulation (17) . The principal drivers of embryonic and post-natal lymphatic growth are VEGF-C and VEGF-D acting through the VEGFR3 receptor whose activation triggers signals via major growth/survival pathways mediated by PI3K/ AKT and RAS/ERK (18) . Numerous auxiliary gene products regulate lymphatic growth and may contribute to vessel dysmorphogenesis. These include angiopoietins 1 and 2, VEGF-A, basic fibroblast growth factor and hepatocyte growth factor. The elaboration of factors such as CXCL12 (SDF-1), plateletderived growth factor and insulin-like growth factor 1 may influence lymphangiogenesis indirectly through VEGF induction or pericyte recruitment (17) . It is in the context of these factors that we evaluated the lymphangiogenic potential of LECs from five independent patient lesions. Furthermore, this phenotype was related to the presence of somatically acquired activating PIK3CA mutations present in each lesion.
RESULTS

Clinical and cellular features of LMs and derived LECs
With the approval of the Institutional Review Board at the Cincinnati Children's Hospital and Medical Center, we obtained de-identified tissue samples from patients who had undergone surgical or sclerotherapy treatment for LMs. Lesions included lymphatic blebs, microcystic samples or large macrocystic lesions accompanying overgrowth conditions (Fig. 1A) . Patient 558 was diagnosed with CLOVES, and underwent surgery to debulk a substantial truncal LM with fatty overgrowth. Patient 837 was diagnosed clinically and radiologically with a CVLM with soft tissue overgrowth affecting the left pelvis and leg. Boney overgrowth was associated with the left foot. Fluid aspirate was obtained from a large gluteal cyst. Patient 935 was diagnosed with CVLM affecting the trunk, left pelvis and leg. No boney overgrowth was noted. Thromboses and postcontrast enhancement, indicating a venous component, were seen by MRI. The source of tissue was a debulked pelvic LM. Patient 1152 was diagnosed with a mixed (micro-and macrocystic) LM of the lower abdomen, buttocks, upper thigh and genital region, for which surgical debulking was performed. Finally, patient 1165 underwent surgery to debulk a microcystic lesion of the tongue, neck and pharynx. Radiographic examination confirmed the diagnosis of LM.
Resected lesions were examined histologically to verify their identity as LMs. In the case of patient 837, cells were isolated from cystic fluid aspirates prior to sclerotherapy, and a histologic examination was not performed. In the four remaining cases, there was extensive infiltration of stromal tissue by dilated lymphatic channels lined with PROX1-positive cells (Fig. 1B , left panel). PROX1 is a definitive marker for LECs (19) . Immunostaining for aSMA highlighted the unusual and variable muscularization of lymphatic vessel walls typical of these lesions (Fig. 1B, right panel) . Following tissue disaggregation or centrifugation of aspirated cells, cell populations were expanded in endothelium growth medium (EGM-2MV, Lonza) and fractionated by immunomagnetic separation on the basis of CD31 expression. CD31-positive endothelial cells were predominantly PROX1-positive, revealing cell populations consisting mostly of LECs. A second selection was performed on the basis of PDPN expression (20) , producing homogeneous populations of PROX1-and PDPN-positive LECs (Supplementary Material, Fig. S1 ). The cell morphology displayed by the LM-LEC populations was similar to that of the normal dermal LECs (dLyNeo cells) used as control cell populations for our comparative analyses (not shown).
Prior to genetic investigations, we sought evidence of growth or functional anomalies in comparisons with normal dermal LECs. Doubling times of the isolated LM-LECs varied widely (Table 1 ), but accelerated growth was evident in four of the five LM-LEC populations. Enhanced lymphangiogenic capacity was exhibited in spheroid sprouting assays conducted in the presence or absence of vascular endothelial growth-factor C ( Fig. 2A and  B) . Spheroids of dLyNeo cells embedded in collagen gels failed to sprout in the absence of exogenous growth factors, whereas sprouting was visible from spheroids of each LM-LEC population when cultured in growth-factor-free medium (Red2MV). Supplementation of Red2MV with VEGF-C promoted sprouting from dLyNeo spheroids and further enhanced the sprouting from spheroids of LM-LECs. Enhanced proliferation and sprouting, and the reduced dependence on exogenous growth factors attested to the heightened lymphangiogenic potential of LECs from patient malformations. These acquired attributes of LM-LECs, passaged free of stromal cell influence, were deemed likely to reflect an intrinsic genetic change.
Gene sequencing of lesion-derived LECs
A genetic basis for the heightened lymphangiogenic sprouting of LM-LECs was explored. Patient 558, having been diagnosed with CLOVES, was expected to bear a mutation in PIK3CA based on the recent association of activated PIK3CA alleles with CLOVES (11) . We confirmed the presence of an activating PIK3CA allele, c.3140A.T (p.H1047L), in our CLOVES (558) cell population by direct PCR sequencing (Fig. 3A , based on RefSeq. NM_006218.2). Mutant and wild-type sequences overlap at the position of the exchanged base indicative of allele heterozygosity. The mutation was not present in the non-endothelial cell population derived from the same patient (Fig. 3A) indicative of its mosaic presence.
Given the similar phenotype shared by the five LM-LEC populations, we screened all samples for the presence of activating PIK3CA alleles. LM-LEC genomic PIK3CA sequences spanning known mutation hotspots (corresponding to codons E542, E545 and H1047) were amplified as previously described (11), and sequenced. Common PIK3CA variants were discovered in all cell populations. Patient 1152 LECs carried a PIK3CA mutation at c.1634A.C, yielding a known oncogenic p.E545A substitution (21) (Fig. 3A) . LM-LECs from patient 837 carried another PIK3CA allele (c.1624G.A, p.E542K). The analysis of LECs from patients 1165 and 935 also revealed c.1624G.A/ p.E542K mutations. For these latter two samples, the mutant allele was not detected in their CD31-negative co-isolated cell counterparts (not shown), indicative of tissue mosaicism.
For the rapid identification of PIK3CA alleles in lesion samples, we developed an allele-specific PCR assay based on the amplification-refractory mutation system (ARMS-PCR). Primer pairs were designed to detect the four oncogenic alleles already identified in LMs, and a fifth common activating allele with an H1047R substitution. The presence of the PIK3CA (E545A) allele in three random 1152 LM tissue samples was demonstrated by this technique (Fig. 3B) . A weak positive signal relative to the CD31-selected LM-LECs is consistent with allele mosaicism. Separately, the p.E542K allele was detected in samples of 837 cells, 935 tissue and 1165 tissue (Fig. 3B , right panel). Sequential dilution of PIK3CA p.E542K sequences (present in LM-LEC 837 DNA) with genomic DNA bearing wild-type sequence, gave an indication of the sensitivity of ARMS-PCR in these screens. Levels of allele mosaicism in the 1 -5% range were reliably detected. Allele mosaicism was indicated for 935 and 1165 lesion samples as evinced in comparisons of LM-LEC cultures with lesion tissue. Interestingly, there was an apparent difference in E542K PIK3CA allele abundance among 837, 935 and 1165 LM-LEC cultures. To explore this possibility further, relevant PIK3CA sequences from 1165 and 935 genomic DNA were PCR amplified, cloned and sequenced. Nine of 25 (36%) 1165 clones, and 8 of 20 (40%) 935 clones, bore the p.E542K allele. Not only did this result suggest a more equal abundance of the PIK3CA allele in these two populations, it suggested its heterozygous presence in most cells of the respective cultures (approaching 80% of the cells). While ARMS-PCR is 
Activation of growth pathways in LM-LECs
PIK3CA somatic mutations have been correlated with the hyperactivation of AKT and enhanced cellular growth in the context of CLOVES and cancer (11, 21) . We investigated the activation of the PI3K/AKT signaling pathway in LM-LECs by measuring levels of constitutive phospho-S473-AKT, versus total AKT, in cell lysates by western blot analysis (Fig. 4A ). As expected, based on the presence of activating PIK3CA mutations in all of our lesions, the five cell cultures displayed significantly elevated AKT activation (Fig. 4B ). The expression of PTEN, a major negative regulator of PI3K activity (22) , was assessed for a possible role in PI3K hyperactivation in LM-LECs. We found no evidence for an abnormal down-regulation of PTEN expression at the gene or protein level ( Fig. 4A and C) .
The steady-state status of ERK activation was explored as a possible contributor to growth enhancement. Vascular endothelial growth-factors signal through MEK/ERK, as well as PI3K (18) . Moreover, given the crosstalk between the PI3K/AKT and MEK/ERK pathways, MEK/ERK signaling could have a regulating role in PI3K activity in endothelial cells (23) . Cell levels of phosphorylated ERK1/2, indicative of MEK/ERK activation, are shown in Figure 4A and D. Cells from 1165 to 935 displayed elevated ERK activation. However, this was not a common feature of LM-LECs as the other three LM-LEC populations displayed reduced levels of constitutive ERK phosphorylation.
Lymphangiogenic gene expression profiles of isolated LM-LECs
LM-LEC populations were characterized with respect to the expression of lymphangiogenic genes to identify (i) secondary factors contributing to dysregulated growth and (ii) potential biomarkers distinguishing LM-LECs on the basis of their individual mutations. VEGF-C and angiopoietin 2 (ANG2) are lymphangiogenic drivers that signal through PI3K/AKT and MEK/ ERK pathways (24, 25) . In turn, PI3K activation is known to regulate the expression of both these factors (25, 26) . Transcriptional analyses by qRT-PCR revealed in LM-LECs an elevated level of VEGFC expression compared with control LECs. This correlated with generally higher levels of secreted VEGF-C, as detected by ELISA-based measurements of conditioned medium ( Fig. 5A and B) . If endogenous VEGF-C expression contributed to the observed enhancements in lymphangiogenic activity it would appear to be factor-driven, rather than receptor-driven, as the levels of VEGFR3/FLT4 transcription were unaltered in LM-LECs (Fig. 5C ). Also striking in these cultures was the reduced level of ANG2 transcription, which correlated with low levels of cell-associated and secreted ANG2 protein ( Fig. 5D and E) .
Elevated VEGF-C expression contrasted with normal transcriptional levels of VEGF-A and VEGF-D (Fig. 6A and B) . VEGF-A and -D can also promote lymphangiogenesis (18, 27) . Next, we explored the possible involvement of the ligandreceptor pair of CXCL12 (SDF-1) and CXCR4. CXCL12/ CXCR4 mediates tube formation and migration of LECs, activating ERK and AKT pathways in the process (28) . The modulation of CXCR4 expression in endothelial cells may affect the autocrine -paracrine roles of CXCL12 during vessel maturation (29) . CXCR4 transcription was much reduced in all LM-LEC populations, while the expression of its ligand CXCL12 was variable ( Fig. 6C and D) . Finally, we examined COX2 expression levels. COX2 converts arachadonic acid to prostaglandin H2, an intermediate in the biosynthesis of prostaglandins that possess angiogenic activity. COX2 has been shown to be associated with enhanced lymphangiogenesis in various tumors (30) . In general, mRNA and protein levels of COX2 were elevated in LM-LEC cultures ( Fig. 6E and F) . In summary, a mixed lymphangiogenic profile of sustained VEGF-C production, low ANG2 expression, low CXCR4 transcription and elevated COX2 expression was common to the five lesion-derived populations of LECs.
Susceptibility of LEC cultures to cell signaling inhibition
We evaluated the roles of PI3K/AKT/mTOR activation and VEGFR3 activation in the enhanced growth of LM-LECS by measuring the effects of selective inhibitors in cell proliferation assays. A potent inhibitor of the PI3K p110a catalytic subunit (GDC-0941) (31) effectively inhibited the proliferation of LM-LECs but with no specificity relative to control LECs (Fig. 7A) . In contrast, four of five LM-LEC cultures were more sensitive to the mTOR inhibitor Rapamycin (Sirolimus), a drug with clinical efficacy in the treatment of LMs (8) . Downstream of PI3K/AKT, mTOR mediates multiple cell growth signals (23) . Cultures of the slower growing 1165 LM-LECs appeared to be less sensitive to this drug than the other LM-LECs (Fig. 7B ), though they remained marginally more sensitive than control LECs. Finally, a potent and specific inhibitor of the VEGF-C receptor (VEGFR3), SAR131675 (32) was tested, in part to evaluate the growth contributions of endogenously expressed VEGF-C. The growth of LECs bearing PIK3CA mutations was not inhibited by drug concentrations (10 28 -10 26 M) that effectively inhibited the growth-factordriven proliferation of normal LECs (Fig. 7C) . Measurements of 1165 LM-LEC sensitivity to SAR131675 were unobtainable because of their slow growth in the reduced medium used in these experiments. The relative resistance of LM-LECs to the VEGFR3 inhibitor is an indication that receptor activation is not a significant contributor to enhanced growth in LM-LEC and that endogenously expressed VEGF-C is not likely a major driver of growth in LM-LEC cultures.
Scope of PIK3CA mutations in LMs
To explore the broader significance of PIK3CA mutations in LMs, we screened nine more recently derived LM endothelial cell cultures not otherwise characterized in this study, along with samples of LM, VLM and CVLM tissue deposited in our Vascular Anomalies Tissue Repository. Genomic DNA was analyzed by direct sequencing of hotspot regions within the helical domain (E542, E545) and kinase domain (H1047) of PIK3CA (cell cultures only) or by implementing ARMS-PCR to detect mutations related to E542K, E545A, E545K, H1047 R and H1047L alleles (archived tissue). Results for all screened cells and tissues (with the five subjects central to this report) are presented in Table 2 . Subjects were grouped by clinical presentation as (i) LM in the head and neck region, (ii) LM on the trunk or extremity, (iii) CVLM with no overgrowth and (iv) CVLM with overgrowth. In each case, tissue or cells were derived from debulked or aspirated LMs. All nine recently derived LM-LEC populations bore one of the five common PIK3CA alleles. Thus, 14 of 14 derived LEC populations, representing each clinical entity, possessed a common activating PIK3CA allele. Among archived samples, 7 of 8 LM and 5 of 7 CVLM samples were positive for an activating PIK3CA allele. Only three archived VLM samples were tested and each was negative for the screened mutant alleles.
DISCUSSION
LECs derived from five independent LM (LM-LECs) displayed growth enhancement in vitro coincident with an elevation in PI3K/AKT activation. All five LEC populations, and nine more recently derived LM-LEC populations, were discovered to contain genomic mutations in PIK3CA, the catalytic p110a subunit of PI3K. The PIK3CA mutations identified are allelic hotspots and correlate with PI3K activation (21) . In addition, activated PIK3CA alleles were detected in 12 of 15 archived tissue samples. In total, 26 of 29 (89%) samples of LM/CVLM tissue were identified bearing activating PIK3CA alleles. Our assays were limited to the identification of common hotspot mutations, but not all reported activating alleles. The presence of less common activating alleles may account for the three negative results we obtained with archived LM/CVLM samples. The presence of these common activating PIK3CA alleles in LM samples is similar to allele frequencies associated with PIK3CA-mutated cancers (33) .
The association of LMs with activated PI3K-AKT linked syndromes (CLOVES, KTS and Proteus) is consistent with our association of activated PI3K activity in LMs removed from overgrowth conditions. LMs would appear to be distinct genotypically, as well as phenotypically, from lymphatic anomalies observed in overgrowth syndromes underpinned by activating RAS-MAPK mutations (Parkes Weber and Noonan). In these latter overgrowth syndromes, lymphatic dysplasia and lymphangiectasia were featured (15, 16) . The absence of LMs in certain PIK3CA-related overgrowth syndromes (34) can be expected if the acquired PIK3CA alleles occurred in a cell outside the vascular lineage. For non-syndromic LM, we suspect that the acquisition of an activating PIK3CA allele occurred late in the differentiation process, within a committed endothelial cell. The endothelial origin of these lesions is in contrast to infantile hemangiomas, in which genetic reprogramming appears to originate in a vascular progenitor cell. These stem cells differentiate into abnormal pericytes which fail to regulate endothelial organization (35) . The abnormal lymphangiogenic phenotype, we describe for LM-LECs, is independent of stromal cell/ anatomical influence and reflects an inherent pathologic change.
A recent report alludes to a genotype -phenotype association of different PIK3CA alleles with clinically distinct segmental overgrowth syndromes [fibroadipose overgrowth (FAO); hemihyperplasia multiple lipomatosis (HHML); macrodactyly, megalencephaly syndrome and CLOVES] (34). Specifically, codon 1047 substitutions (in the catalytic domain of PI3K) were present in 23 of 25 cases of FAO, HHML and macrodactyly as detected in affected bone, adipose tissue, muscle or skin. In contrast, codons 542 and 545 (in the helical domain) were disproportionately substituted in alleles detected in CLOVES patients (6 of 9). As only 15 total subjects manifested vascular malformations, and malformations are a clinical feature of CLOVES, few of the FAO/HHML/macrodactyly group displayed vascular malformations. Hence, codon 1047 mutations were more often associated with overgrowth than vascular malformations. A bias was observed in our data as well. LMs with no associated overgrowth or mixed vascular components predominantly carried helical domain mutations (12/15 LMs, 75% codon 542 and 545 substitutions; Table 2 ). However, in more complex clinical settings (i.e. CVLM with or without overgrowth), codon 1047 mutations were better represented (55%). These correlations may be related to allele-specific differences in AKT activation and downstream signaling. Allele-specific impact on LEC function, disease progression and susceptibility to treatment requires further investigation.
Our five populations of PIK3CA-mutant LECs shared a common lymphangiogenic signature relatable to the overactivation of PI3K/AKT signaling. They exhibited elevated levels of phosphorylated AKT, elevated VEGF-C and COX2 expression, enhanced sprouting activity in the absence of growth factor, reduced ANG2 expression and release, and reduced CXCR4 expression. This profile may explain some of the gross and microscopic characteristics of LMs. The distil lymphatic system is composed of primary lymphatics with a discontinuous basement membrane (absorptive component) and pre-collectors that are both absorptive and propulsive (36) . The scattered association of smooth muscle cells on pre-collectors (facilitating propulsion) develops in an AKT-and ANG2-dependent fashion. The PI3K/AKT axis is critical for lymphatic vessel maturation (37) as it perpetuates an activating loop by inducing VEGF-C expression. ANG2, in contrast, is repressed by PI3K activity, involving the phosphorylation-dependent inactivation of FOXO1 and FOXO3a, transcription factors that are essential for ANG2 expression (38) . Thus, up-regulated PI3K/AKT signaling in LM-LECs conceivably elevates VEGF-C expression and decreases ANG2 expression, advancing the characteristics of stable, more muscularized vessels. The down-regulation of CXCR4 may be relevant to this process, as shown in maturing blood vessels (29) . Vessel dilation and expansion within LMs may be promoted by the overactivation of COX2. PI3K/AKT enhances COX2 expression, by activating the NF-kB transcriptional program (39, 40) . In turn, COX-2 promotes lymphangiogenesis via its products, inflammatory prostanoids, which can also induce lymphatic vessel dilation (30) .
The potential of LM-LECs to exert a positive paracrine effect on lymphatic vessel growth and activation limits our interpretation of the pathologic impact of PIK3CA mutations. It is equally plausible that abnormal vessels are lined exclusively by mutated LECs, or that cells in affected vessels walls are themselves mosaic with respect to PIK3CA. In the latter scenario, wild-type LECs could be abnormally activated by factors elaborated by mutant cells. Since abnormal vessels can lie in proximity to normal vessels, our LEC populations were likely mosaic by either scenario in the early stages of isolation. Allele representation in isolated LECs will be influenced further by any intrinsic growth advantage conferred by an activated PIK3CA allele. Hence, allele representation in our cultures may not accurately reflect their representation in vivo. The etiopathologic effect of activated PIK3CA alleles may be paracrine, intrinsic or permissive.
The LM-LEC cultures 935 and 1165 were distinguished by increases in constitutive ERK1/2 activation. The effect seems unrelated to the acquired PIK3CA mutation as 935, 1165 and 837 populations bear the same E542K allele. Furthermore, these cells differ with respect to AKT activation and growth rates. We suspect that differences in background genetics or the presence of additional mutations contribute to phenotypic profiles. Oncogenic activation in the absence of additional permissive mutations can often lead to restrictive cell growth such as through the induction of senescence. Thus, the acquisition of permissive mutations may explain differences in the observed phenotypes of our LM-LEC populations (41) . Combined PI3K/AKT and MEK/ERK activation is consistent with lymphangiogenic signaling downstream of VEGFR3 (18) . However, LM-LEC cultures were generally insensitive to VEGFR3 inhibition suggesting that receptor activation (inherent or driven by endogenous VEGF-C expression) was not a major contributor to growth in any of the LM-LEC cultures. The contribution of additional mutations to LM-LEC dysfunction remains unresolved.
Variability in the clinical presentation of LMs may be reflected in susceptibility to applied drug treatments. For that reason, LM-LEC cultures will be useful in screening the multiple PI3K-AKT-mTOR targeted drugs under development for cancer treatment. Further investigation into alternative pathways downstream of AKT may reveal more specific targets. We continue to explore the cellular features common to all LM-LEC populations, as well as distinguishing differences, with the hope of identifying useful pathological profiles. Appreciating the unique genetics and underlying biochemical phenotype of LM-LECs would be instructive in the design of generally effective treatments, as well as personalized approaches as they are needed.
MATERIAL AND METHODS
Surgical specimens, cell isolation and culture
Tissue and fluid were obtained from patients undergoing surgical resection or sclerotherapy in the reductive treatment of LMs. 
Immunofluorescence and immunohistochemistry
For the identification and verification of LEC populations, cells were plated in multi-well chamber slides and immunostained following cold methanol fixation with rabbit anti-PDPN (p5374, Sigma-Aldrich) and rabbit anti-PROX1 (ab38692, Abcam, Cambridge, MA, USA) separately. Visualization was achieved using goat anti-rabbit Alexa Fluor 488 secondary antibody (Life Technologies, Grand Island, NY, USA). Nuclei were counterstained with DAPI fluorescent stain (Life Technologies). The immunostaining of tissue samples was performed on deparaffinized thin sections cut from formalin-fixed blocks embedded in paraffin. Serial sections were reacted with PROX1 antibody and aSMA antibody (Thermo Fisher Scientific, Waltham, MA, USA) separately, and visualized with anti-rabbit HRPconjugated secondary antibody followed by DAB peroxidase substrate (Vector Labs, Burlingame, CA, USA).
Angiogenic sprouting assay
The sprouting assay was based on a published procedure (42) . Briefly, spheroids were formed from 1000 LECs suspended in Red2MV with 0.24% high viscosity methocel (Sigma-Aldrich) in the wells of a 96-well round-bottom plate. After 24 h of culture, the spheroids were collected by centrifugation, suspended in 1.5 mg/ml collagen type I (BD Biosciences, San Jose, CA, USA) containing 0.6% methocel, and cultured in Red2MV or Red2MV + VEGF-C (100 ng/ml). On average, 12 spheroids were embedded in 0. Table S1 . For protein expression, cells were lysed in RIPA buffer containing protease inhibitor cocktail (Santa Cruz Biotechnology, Dallas, TX, USA), sonicated briefly and clarified by centrifugation. Protein aliquots (5 -20 mg) were fractionated by SDS -PAGE in 4 -15% gels, blotted onto PVDF membranes (Bio-Rad) and probed with the following antibodies: rabbit anti-PTEN (#9188), rabbit anti-COX2 (#12282), rabbit anti-AKT (#4691), rabbit anti-phospho-AKT (#4060), rabbit anti-ERK1/ 2 (#4695) and rabbit anti-phospho-ERK1/2 (#4370) (Cell Signaling Technologies, Danvers, MA, USA), mouse anti-GAPDH (#10R-G109a, Fitzgerald Industries International, Acton, MA) and mouse anti-ANG2 (MAB0983, R&D Systems, Minneapolis, MN, USA). HRP-conjugated secondary antibodies and ECL substrate were obtained from Bio-Rad. Membranes were stripped with Restore Plus (Thermo Fisher) and probed repeatedly. VEGF-C in culture media was measured by ELISA (R&D Systems, Minneapolis, MN, USA).
DNA sequencing and cloning of PIK3CA sequences PIK3CA mutations were confirmed by direct sequencing of PCR amplification products generated from targeted genomic sequences in isolated LM-LECs as previously reported (11) .
An alternative PIK3CA primer pair (Supplementary Material, Table S1 ) was used to amplify PIK3CA exon 9 to verify p.E545-related base substitutions. Relative abundance of wildtype and mutant E542K PIK3CA alleles in 1165 and 935 was estimated by isolation of genomic DNA from these cell populations and PCR amplification of exon 9 using Ex Taq (Clontech), 2 mM MgCl 2 , 200 nM primers and 250 mM dNTPs. The 3 ′ A terminal overhang was removed using T4 polymerase (Thermo Fisher Scientific) in the presence of 250 mM dNTPs at 118C for 20 min. The PCR product was then subcloned into the Zero Blunt TOPO PCR Cloning Kit for Sequencing (Life Technologies) and individual colonies were screened either by sequencing or by ARMS-PCR to determine whether the insert was wildtype, E542K mutant or pseudogene sequence from 22q11.2.
Screening for somatic mutations in archived tissue
LM samples were collected from the Cincinnati Children's Hospital Vascular Malformations Tissue Repository. Genomic DNA was isolated from 25 mg of frozen tissue using the PureLink DNA isolation kit (Life Technologies). Allele-specific PCR primers were designed for E542K, E545A, E545K, H1047L and H1047R mutations (see Supplementary Table 1 ) and used to test the isolated DNA by ARMS-PCR. E542K, E545K, H1047L and H1047R primers were designed based off previously published allele-specific primers (43) and their specificity confirmed by testing allele-containing gDNA identified by direct sequencing (Supplementary Material, Fig. S2 ).
Drug inhibition assays
Cell proliferation in the presence of inhibitors was measured by WST-1 assay (Clontech). Drugs (Rapamycin/Sirolimus, GDC-0941 and SAR131675; Selleck Chemicals, Houston, TX, USA) were dissolved in DMSO and serially diluted in growth medium. LECs were seeded at 1000-2000 cells per fibronectincoated well of a 96-well plate in EGM-2MV and cultured in humidified 5% CO 2 at 378C. For rapamycin and GDC-0941 measurements, drugs were added in EGM-2MV 2 h post-seeding. For SAR131675 inhibition studies, EGM-2MV was replaced after 16 h with Red2MV+/2 VEGF-C (100 ng/ml) plus inhibitor. Cells were cultured for 48 or 96 h in the presence of drug, treated with WST-1 reagent and absorbance read after 30 and 60 min of culture at 378C.
Statistical analyses
Inhibition plots were generated by GraphPad Prism version 6.01 (GraphPad Software). Significance was determined to P , 0.05 by one-way ANOVA analysis or Student's t-tests. 
